A-HeFT: old dog, new endothelial tricks.
In conclusion, reduced nitric oxide bioactivity contributes to cardiac and vascular remodeling. Nitricoxide-enhancing therapy can slow cardiac andvascular remodeling. African-Americans with heart failure exhibit nitric oxide deficiency and a dramatic benefit from nitric-oxide-enhancing therapy. The potential benefit of this therapy in other groups with heart failure and in other vascular remodeling disease processes requires further study.
Cohn
Jay N
JN
Rasmussen Center for Cardiovascular Disease Prevention, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA. cohnx001@umn.edu
D001741:Black or African American; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D006333:Heart Failure / Q000188:drug therapy / Q000208:ethnology / Q000503:physiopathology*; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents; D006830:Hydralazine; D007548:Isosorbide Dinitrate